Navigation Links
Pathwork Diagnostics Collaborates With Guy's and St Thomas' on Tissue of Origin Test Validation in the UK
Date:12/9/2008

London Hospitals First in UK to Perform Study Utilizing Pathwork Tissue of Origin Test

SUNNYVALE, Calif., Dec. 9 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced today a collaboration with Guy's and St Thomas' NHS Foundation Trust in London. Guy's and St Thomas' will be the first hospitals in the United Kingdom to conduct a research study on the Pathwork(R) Tissue of Origin Test, which aids in the diagnosis of hard-to-identify tumors.

"We're extremely excited about entering into this partnership with Guy's and St Thomas' NHS Foundation Trust," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "In this study, pathologists and oncologists at Guy's and St Thomas' will not only be able to validate the test for use in their institution, but more importantly, soon be able to use information generated to help them determine the most effective, cancer-specific treatment regimen for hard-to-diagnose cases."

In the collaboration, Dr. Giuseppe Culora, the clinical director, and Dr. Eugene Halligan, the scientific director, are performing a proof-of-concept validation study. "Since patients with cancer of unknown primary have a very poor prognosis, we hope that with this novel diagnostic test our oncologists will have new information at their fingertips to guide treatment and be able to offer a better standard-of-care for our cancer patients," said Dr. Culora.

The Pathwork Tissue of Origin Test uses a microarray to measure the RNA expression pattern, comprising more than 1,500 genes, in the tumor and compares it to expression patterns of a panel of 15 known tumor types, representing 60 morphologies overall, to help determine the tumor's origin. Earlier this year, Pathwork became the first U.S.-based company to receive U.S. Food and Drug Administration (FDA) clearance for a molecular diagnostics test under
'/>"/>

SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
2. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
3. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
4. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
5. Hypertension Diagnostics Announces Fiscal Year 2007 Results
6. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
7. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
10. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
11. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Today, Therapy Changes released ... Me?” The guide outlines common questions an individual may ... to common types of groups an individual can attend. ... the interventions of the therapist, but also from observing ... members,” says Rochelle Perper, Ph.D. and founder of Therapy ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud ... a contemporary marketing presence and visually solidifies the ... Friendship Senior Options,” said Stephen A. Yenchek, president ... the logo, we are making sure that our ... their families.” , Friendship Village is a retirement ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
(Date:9/2/2014)... return to the emergency department within a few days of ... symptoms and have lost trust in other parts of the ... published online today in Annals of Emergency Medicine ... ). , "When asked why they did not ... symptoms were too severe to wait until their scheduled appointment ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... cancer-prevention gene in the response to drug treatment for childhood ... known as the guardian of the genome, is known for ... gene are associated with a high incidence of cancer due ... tumours. , In childhood cancers such as neuroblastoma, p53 mutations ...
... tuning out distractions can be learned , MONDAY, Nov. ... a person,s brain is organized, says a U.S. study that ... training. , All the participants were between the ages of ... than 10 years experience as a band or orchestra director ...
... FDA says clotting drug poses increased death risk, while company ... (HealthDay News) -- Bayer AG suspended worldwide sales of Trasylol, ... on Monday following a request from the U.S. Food and ... for safety reasons. , The FDA cannot identify a patient ...
... HONG KONG, Nov. 5 Mass Financial Corp. ... a lawsuit in the Supreme Court of,British Columbia, ... for breach of contract and contract interference. In ... Michael Smith, President of MASS said the ...
... Inc. (Nasdaq: ALTH ) today reported financial results for ... 30, 2007, the,Company reported a net loss of $9.3 million, ... $8.1 million, or ($0.15) per share, for the third,quarter of ... Company,reported a net loss of $28.1 million, or ($0.43) per ...
... 5 Hooper Holmes,Inc. (AMEX: HH ) announced ... after-market on Thursday, November 8, 2007. The Company,will host ... 11:00 a.m.,Eastern Time. To participate in the third ... Hooper Holmes. A live web cast,will be hosted on ...
Cached Medicine News:Health News:Training, Experience Can Change How Brains Work 2Health News:Trasylol Pulled From Worldwide Market 2Health News:Trasylol Pulled From Worldwide Market 3Health News:Trasylol Pulled From Worldwide Market 4Health News:Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 3Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 4Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 5Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 6Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 7Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... -- Donald Spector , a renowned celebrated entrepreneur ... a Wearable Biosensor, which will issue today, September 2, ... Mr. Spector holds some of the earliest patents in ... by New York College of Health Professions, which has ... intellectual properties.  New York College noted that the Wearable ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... an overview of the company at the Morgan Stanley Global ... , Presentation date: Tuesday September 9, 2014 , ... live webcast and 30-day archive of this presentation will be ... Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... historic open letter to the World Health Organization ... Drugs (CoMeD) , and the United Methodist Women are seeking ... vaccines.  Currently, the mercury-based preservative Thimerosal, which is 49% mercury ... much of the world, despite the fact that it is ...
... Texas, March 15, 2012  OxySure® Systems, Inc. (OTCBB: ... emergency oxygen solutions with its "oxygen from powder" ... a Supplier Agreement ("Agreement") with W.W. Grainger, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In terms ...
Cached Medicine Technology:Global Call for Mercury-free Vaccines Issued 2OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA"....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: